.jpg)
Paris, May 6, 2010 - Biomedical Diagnostics (BMD), an in vitro diagnostics company specializing in the diagnosis of autoimmune diseases, today announced that its LISA TRACKER Premium kits had obtained CE mark approval.The LISA TRACKER Premium kits are innovative monitoring tools for the simultaneous assay of TNFα (a cytokine involved in disease progression), anti-TNF therapeutics (Infliximab, Etanercept and Adalimumab) and neutralizing, anti-drug antibodies (ADAs). The correlation of these three parameters is essential for defining and predicting a patient's treatment response. It known that the development of ADAs reduces a treatment's efficacy and induces the long-term resurgence of disease symptoms. In combination with clinical data, the assay results enable physicians to establish the patient's resistance profile and thus optimize the management of certain autoimmune diseases (such as chronic rheumatoid arthritis and ankylosing spondylitis in rheumatology, Crohn's disease and hemorrhagic colitis in gastroenterology and psoriatic arthritis in dermatology)...
...
...About Biomedical Diagnostics (BMD):
With more than twenty years’ experience in the in vitro diagnostics (IVD) market, BMD has acknowledged expertise in the development, production and marketing of high quality, innovative products. The company develops and supplies effective high throughput solutions, based notably on Luminex® technology for the diagnosis of auto immune diseases. BMD is now aiming to become France's leading distributor of innovative IVD products. By building on its strength in the autoimmune disease testing market, the company is building a reputation as a major European player in the development of "companion" diagnostics as part of a pro-active strategy for partnering with biotech and pharma companies... Biomedical Diagnostics' Press Release - communiqué de presse Biomedical Diagnostics en français -
